Carbamazepine PBPK model

[LMFuhr]

Dear OSP-community,

We have been working on a parent-metabolite PBPK model of carbamazepine and its main metabolite carbamazepine-10,11-epoxide.

The model was developed to be used in DDI modeling with carbamazepine as CYP3A4 and CYP2B6 substrate and inducer and was evaluated in a DDI network with

• erythromycin (CYP3A4 inhibitor)
• alprazolam and simvastatin (CYP3A4 substrates)
• bupropion (CYP2B6 substrate)
• efavirenz (CYP3A4 and CYP2B6 substrate and inducer)

The corresponding manuscript, including comprehensive documentation, has been published online in Pharmaceutics and the carbamazepine PBPK model as well as PK-Sim projects of the predicted DDI studies can be found here.

Related publication:
Fuhr, L.M.; Marok, F.Z.; Hanke, N.; Selzer, D.; Lehr, T. Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and Its Drug–Drug Interaction Potential: A Physiologically Based Pharmacokinetic Modeling Approach. Pharmaceutics 2021, 13, 270.

Best regards,
Laura